Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
H Li, Y Yang, W Hong, M Huang, M Wu… - Signal transduction and …, 2020 - nature.com
Based on engineered or bacterial nucleases, the development of genome editing
technologies has opened up the possibility of directly targeting and modifying genomic …
technologies has opened up the possibility of directly targeting and modifying genomic …
Roles and mechanisms of alternative splicing in cancer—implications for care
SC Bonnal, I López-Oreja, J Valcárcel - Nature reviews Clinical …, 2020 - nature.com
Removal of introns from messenger RNA precursors (pre-mRNA splicing) is an essential
step for the expression of most eukaryotic genes. Alternative splicing enables the regulated …
step for the expression of most eukaryotic genes. Alternative splicing enables the regulated …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment
AC Garrido-Castro, NU Lin, K Polyak - Cancer discovery, 2019 - AACR
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
[HTML][HTML] A decade of clinical development of PARP inhibitors in perspective
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Abstract ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in
BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein …
BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein …
A protein interaction landscape of breast cancer
INTRODUCTION Advances in DNA sequencing technology have enabled the widespread
analysis of breast tumor genomes, creating a catalog of genetic mutations that may initiate or …
analysis of breast tumor genomes, creating a catalog of genetic mutations that may initiate or …
PARP inhibitors: enhancing efficacy through rational combinations
D Bhamidipati, JI Haro-Silerio, TA Yap… - British journal of cancer, 2023 - nature.com
Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …